Keros Therapeutics annual debt-to-equity ratio
2020
2021
2022
2023
2024
2025
Keros Therapeutics Debt-to-Equity Ratio Growth & History (KROS)
Keros Therapeutics's debt-to-equity ratio was 0.06 for fiscal 2025.
View full Keros Therapeutics company overviewKeros Therapeutics annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.06 | 0.02 | +68.78% |
| 2024 | 2024-12-31 | 0.03 | −0.01 | −24.10% |
| 2023 | 2023-12-31 | 0.04 | −0.00 | −9.08% |
| 2022 | 2022-12-31 | 0.05 | 0.04 | +963.88% |
| 2021 | 2021-12-31 | 0.00 | 0.00 | +30.85% |
| 2020 | 2020-12-31 | 0.00 | — | — |
Keros Therapeutics quarterly debt-to-equity ratio
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.06 | 0.03 | +135.95% |
| Q1 2026 | 2026-03-31 | 0.06 | 0.03 | +126.05% |
| Q4 2025 | 2025-12-31 | 0.06 | 0.02 | +68.78% |
| Q3 2025 | 2025-09-30 | 0.02 | −0.01 | −31.56% |
| Q2 2025 | 2025-06-30 | 0.03 | −0.01 | −23.39% |
| Q1 2025 | 2025-03-31 | 0.03 | −0.01 | −19.26% |
| Q4 2024 | 2024-12-31 | 0.03 | −0.01 | −24.10% |
| Q3 2024 | 2024-09-30 | 0.04 | −0.01 | −25.20% |
| Q2 2024 | 2024-06-30 | 0.03 | −0.01 | −22.45% |
| Q1 2024 | 2024-03-31 | 0.03 | −0.01 | −20.63% |
| Q4 2023 | 2023-12-31 | 0.04 | −0.00 | −9.08% |
| Q3 2023 | 2023-09-30 | 0.05 | 0.05 | +2463.20% |
| Q2 2023 | 2023-06-30 | 0.04 | 0.04 | +1247.96% |
| Q1 2023 | 2023-03-31 | 0.04 | 0.04 | +896.66% |
| Q4 2022 | 2022-12-31 | 0.05 | 0.04 | +963.88% |
| Q3 2022 | 2022-09-30 | 0.00 | −0.00 | −68.18% |
| Q2 2022 | 2022-06-30 | 0.00 | 0.00 | +8.18% |
| Q1 2022 | 2022-03-31 | 0.00 | 0.00 | +23.26% |
| Q4 2021 | 2021-12-31 | 0.00 | 0.00 | +30.85% |
| Q3 2021 | 2021-09-30 | 0.01 | −0.00 | −22.28% |
| Q2 2021 | 2021-06-30 | 0.00 | −0.00 | −62.04% |
| Q1 2021 | 2021-03-31 | 0.00 | — | — |
| Q4 2020 | 2020-12-31 | 0.00 | — | — |
| Q3 2020 | 2020-09-30 | 0.01 | — | — |
| Q2 2020 | 2020-06-30 | 0.01 | — | — |
Keros Therapeutics debt-to-equity ratio trends
Over the last five fiscal years, Keros Therapeutics's debt-to-equity ratio increased from 0.00 to 0.06, a change of 0.05. The latest reported quarter, Q2 2026, shows 0.06.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Keros Therapeutics source filings ↗